FDA creates final guidance on approval pathway for biosimilars

The FDA, as part of the Biosimilars Action Plan, is acting to promote competition in the biologic developer market by providing final guidance for “interchangeable” biologics on the pathway to approval, according to a release from the organization.
The FDA stated that its actions will clarify guidelines for developers who want to prove that their “interchangeable” biologics meet the statutory interchangeability standard under the Public Health Service Act.

“Today’s final guidance gives an overview of important scientific considerations in demonstrating

Source link

Related posts

Deep sedation does not improve colonoscopy quality compared to moderate sedation


Morning Break: Another Abortion Ban; Face Transplants 5 Years On; That's Some Massage


Telehealth identifies liver transplantation noncandidates


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy